Author:
Rachayon Muanpetch,Jirakran Ketsupar,Sodsai Pimpayao,Sughondhabirom Atapol,Maes Michael
Abstract
AbstractMajor depressive disorder (MDD) is associated with T cell activation, but no studies have examined the combined effects of T cell activation and deficits in T regulatory (Treg) cells on the severity of acute phase MDD. Using flow cytometry, we determined the percentage and median fluorescence intensity of CD69, CD71, CD40L, and HLADR-bearing CD3+, CD4+, and CD8+ cells, and cannabinoid type 1 receptor (CB1), CD152 and GARP (glycoprotein A repetitions predominant)-bearing CD25+ FoxP3 T regulatory (Treg) cells in 30 MDD patients and 20 healthy controls in unstimulated and stimulated (anti-CD3/CD28) conditions. Based on cytokine levels, we assessed M1 macrophage, T helper (Th)-1 cell, immune-inflammatory response system (IRS), T cell growth, and neurotoxicity immune profiles. We found that the immune profiles (including IRS and neurotoxicity) were significantly predicted by decreased numbers of CD152 or GARP-bearing CD25+ FoxP3 cells or CD152 and GARP expression in combination with increases in activated T cells (especially CD8+ CD40L+ percentage and expression). MDD patients showed significantly increased numbers of CD3+ CD71+, CD3+ CD40L+, CD4+ CD71+, CD4+ CD40L+, CD4+ HLADR+, and CD8+ HLADR+ T cells, increased CD3+ CD71+, CD4+ CD71+ and CD4+ HLADR+ expression, and lowered CD25+ FoxP3 expression and CD25+ FoxP+ CB1+ numbers as compared with controls. The Hamilton Depression Rating Scale score was strongly predicted (between 30 and 40% of its variance) by a lower number of CB1 or GARP-bearing Treg cells and one or more activated T cell subtypes (especially CD8+ CD40L+). In conclusion, increased T helper and cytotoxic cell activation along with decreased Treg homeostatic defenses are important parts of MDD that lead to enhanced immune responses and, as a result, neuroimmunotoxicity.
Funder
AMERI-ASIA MED CO, Ltd
H.M. the King Bhumibol Adulyadej's 72nd Birthday Anniversary Scholarship support PhD scholarship
Thailand Science research and Innovation Fund Chulalongkorn University
Publisher
Springer Science and Business Media LLC
Reference72 articles.
1. World Health Organisation. Depression and Other Common Mental Disorders: Global Health Estimates. Contract No.: WHO/MSD/MER/2017.2 (World Health Organization, 2017)
2. Felger, J. C. Role of Inflammation in Depression and Treatment Implications. In Antidepressants: From Biogenic Amines to New Mechanisms of Action (eds Macaluso, M. & Preskorn, S. H.) 255–286 (Springer, 2019).
3. Eller, T., Vasar, V., Shlik, J. & Maron, E. Pro-inflammatory cytokines and treatment response to escitalopram in major depressive disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 32(2), 445–450 (2008).
4. Liu, J. J. et al. Peripheral cytokine levels and response to antidepressant treatment in depression: A systematic review and meta-analysis. Mol. Psychiatry. 25(2), 339–350 (2020).
5. Więdłocha, M. et al. Effect of antidepressant treatment on peripheral inflammation markers—A meta-analysis. Prog. Neuropsychopharmacol. Biol. Psychiatry. 80(Pt C), 217–226 (2018).